Healthcare and pharma are adopting AI fast in India, but there’s no grant that funds it — and the real constraints are data sensitivity and safety, not money. Here’s an honest map. (dgm implements osFoundry, a separate company’s platform — dgm is an independent integration partner, not osFoundry, and not a funding or medical advisor. General information, not professional or medical advice.)
The funding reality
There is no dedicated scheme funding healthcare providers or pharma firms to adopt AI. Investment is institutional, corporate and VC-driven. Indian healthcare and pharma are running many pilots, with 30–40% productivity gains projected by 2030 — but that’s adoption momentum, not a grant. Organisations generally fund it themselves.
Where AI is being used
Explored further in AI in healthcare and AI in pharma, common areas include:
- Administrative and documentation automation;
- Patient-query and triage support;
- Medical-record search;
- in pharma, research support and document-heavy processes.
The strongest near-term value is often in administrative and operational workflows, not autonomous clinical decisions.
The real constraints: data and safety
- Patient data is highly sensitive under the DPDP Act, so controlled or self-hostable deployment matters most.
- Clinical AI keeps humans in the loop — AI augments clinicians and staff; it does not replace clinical judgement. Validation and oversight are essential.
These outweigh funding questions in healthcare.
Where dgm fits
dgm helps healthcare and pharma organisations adopt AI by implementing osFoundry — self-hostable for patient-data control under the DPDP Act, with humans kept in the loop — for a transparent $399 assessment and $3,999/month (INR approximate; 18% GST domestic). We don’t provide funding, and we don’t position AI as a replacement for clinical judgement; we make controlled adoption practical.
General information, not professional or medical advice. Clinical and regulatory determinations rest with qualified professionals.